common
vocabulari
vaccin
safeti
research
brighton
collabor
focus
initi
effort
develop
standard
case
definit
advers
event
follow
immun
aefi
includ
guidelin
data
collect
analysi
present
date
aefi
case
definit
develop
voluntari
brighton
work
group
endors
norm
bodi
council
intern
organ
medic
scienc
ciom
us
food
drug
administr
fda
european
medicin
agenc
ema
freeli
avail
public
use
wwwbrightoncollaborationorg
brighton
aefi
case
definit
increasingli
use
recogn
common
currenc
allow
greater
eas
compar
vaccin
safeti
studi
evidenc
recent
intern
studi
intussuscept
rotaviru
vaccin
guillainbarrefish
syndrom
narcolepsi
influenza
vaccin
http
elsevi
ltd
issu
critic
import
investig
brighton
collabor
viral
vector
vaccin
safeti
work
group
potenti
recombin
viral
vector
vaccin
wild
type
pathogen
strain
vectorcircul
viru
could
creat
pathogen
strain
b
issu
address
vitro
anim
studi
implic
prior
infect
immunogen
vector
vaccin
prior
infect
relat
virus
may
reduc
vaccin
immunogen
eg
adenovirus
poxvirus
smallpox
vaccin
b
immunogen
subsequ
dose
especi
differ
gene
vector
eg
modifi
poxvirus
adenovirus
address
relev
genet
stabil
replic
recombin
virus
vivo
studi
focus
sequenc
insert
known
area
attenu
b
known
epitop
impact
addit
foreign
gene
pathogen
viral
vaccin
vector
compar
parent
viru
b
test
absenc
revers
virul
perform
attenu
vector
use
absenc
replic
compet
viru
replic
incompet
vector
use
demonstr
public
accept
vector
vaccin
specif
safeti
concern
could
issu
need
forum
discuss
concern
best
commun
risk
benefit
new
approach
gener
public
identifi
request
take
lead
assess
vector
vaccin
effect
innat
immun
possibl
induct
immunosuppress
window
altern
immun
activ
defin
length
time
monitor
aefi
receipt
vector
vaccin
develop
guidelin
archiv
sampl
vector
vaccin
sampl
enabl
potenti
futur
test
assess
inadvert
contamin
adventiti
agent
vaccin
safeti
issu
frequent
promin
postlicensur
set
administ
larger
heterogen
popul
view
continuum
product
life
cycl
begin
prelicensur
consist
brighton
collabor
case
definit
design
use
preand
postlicensur
set
associ
guidelin
collect
analysi
present
vaccin
safeti
data
preand
postlicensur
clinic
studi
includ
templat
protocol
sinc
tradit
method
vaccin
develop
fail
sever
major
human
pathogen
eg
human
immunodefici
viru
hiv
tuberculosi
malaria
new
approach
emerg
biotechnolog
revolut
explor
amongst
new
approach
recombin
viral
vector
provid
effici
mean
heterolog
antigen
express
vivo
thu
provid
promis
platform
develop
novel
vaccin
diseas
pose
challeng
vaccin
develop
veterinari
viral
vector
vaccin
licens
yet
limit
clinic
experi
efficaci
safeti
vector
human
world
health
organ
inform
consult
character
qualiti
aspect
vaccin
base
live
viral
vector
ema
guidelin
qualiti
nonclin
clinic
aspect
live
recombin
viral
vector
vaccin
identifi
sever
issu
critic
import
warrant
investig
includ
recombin
wildtyp
pathogen
strain
explor
public
accept
see
item
tabl
increas
number
viral
vector
enter
human
clinic
trial
urgent
need
establish
appropri
regulatori
measur
ensur
qualiti
safeti
efficaci
need
highlight
recent
develop
plan
expedit
human
trial
two
ebola
vaccin
candid
one
use
chimp
adenoviru
recombin
vesicular
stomat
viru
rvsv
viral
vector
higher
rate
hiv
acquisit
among
particip
step
phambili
trial
receiv
replicationdefect
vector
vaccin
candid
specif
brighton
collabor
improv
abil
anticip
safeti
issu
meaning
assess
interpret
safeti
data
trial
new
viral
vector
vaccin
enhanc
public
confid
safeti
efficaci
encourag
initi
vaccin
research
brighton
collabor
form
viral
vector
vaccin
safeti
work
group
octob
help
standard
collect
analysi
dissemin
safeti
data
regard
viral
vector
vaccin
preand
postlicensur
set
brighton
collabor
work
group
form
identifi
critic
mass
n
initi
interest
individu
academ
govern
industri
volunt
appropri
expertis
interest
vaccin
safeti
virolog
email
exchang
monthli
confer
call
coordin
secretariat
cdc
divis
hivaid
prevent
focus
two
main
set
activ
first
adopt
list
seven
issu
critic
import
need
investig
identifi
consult
live
viral
vector
see
first
seven
issu
list
tabl
ad
four
addit
issu
see
last
four
issu
list
tabl
address
sever
issu
simultan
hope
develop
harmon
guidelin
enhanc
compar
interpret
data
second
recogn
valu
brighton
collabor
standard
case
definit
aefi
work
develop
standard
templat
describ
key
characterist
novel
vaccin
vector
facilit
scientif
discours
among
key
stakehold
increas
transpar
compar
inform
fortuit
intern
aid
vaccin
initi
iavi
develop
intern
templat
tool
assess
riskbenefit
differ
viral
vector
tool
aim
flag
issu
may
either
showstopp
need
care
address
help
priorit
vector
develop
activ
templat
gather
inform
characterist
wild
type
viru
vector
deriv
also
aid
ascertain
known
effect
propos
vaccin
vector
anim
human
manufactur
detail
toxicolog
potenc
preclin
studi
human
use
overal
advers
effect
risk
assess
iavi
kindli
share
tool
adapt
broader
use
standard
templat
collect
key
inform
riskbenefit
assess
viral
vector
vaccin
issu
vaccin
monath
et
al
publish
first
complet
brighton
collabor
templat
riskbenefit
assess
live
viru
vaccin
base
yellow
fever
vaccin
backbon
hope
eventu
developersresearch
viral
vector
vaccin
especi
like
use
human
complet
templat
submit
brighton
collabor
peer
review
eventu
public
vaccin
recogn
desir
inform
need
complet
entir
templat
especi
peer
review
scientif
public
systemat
review
may
current
unavail
new
candid
vector
vaccin
nevertheless
exist
gap
current
knowledg
deter
research
initi
complet
templat
best
abil
gap
may
provid
construct
signal
priorit
area
futur
research
also
recogn
research
sponsor
may
wish
delay
share
inform
proprietari
intellectu
properti
reason
hope
stanc
evolv
develop
viral
vector
vaccin
candid
matur
evalu
human
trial
need
inform
share
transpar
grow
maxim
public
accept
furthermor
like
pace
accumul
new
scientif
knowledg
vaccin
develop
may
rapid
chang
clinic
diagnosi
relev
aefi
case
definit
therefor
brighton
collabor
hope
maintain
templat
dynam
wiki
style
ie
onlin
collabor
edit
help
vector
vaccin
research
commun
seek
assist
identifi
encourag
research
new
viral
vector
vaccin
candid
complet
templat
join
subsequ
vectorspecif
wiki
commun
excit
new
era
vaccin
develop
well
futur
decad
